Q Bio

Next-Generation Health Scan

Andrew Kuzemczak
August 29, 2025

In partnership with

The easiest way to hire globally

Don’t let borders limit your hiring strategy. RemoFirst gives you one platform to legally employ talent around the world—compliantly, affordably, and fast.

We support EOR and contractor payments in 185+ countries with no annual contracts, flat pricing, and full transparency.

Whether you’re a startup or scaling enterprise, you’ll get hands-on support and built-in tools for international payroll, health benefits, taxes, and more.

RemoFirst offers a free tier for contractor management, and EOR fees start at $199/month.

Start hiring globally

Welcome to the 2 new subscribers who have joined Future Human since our last edition! Join 221 other leaders learning about the future of human health by subscribing here:

TL;DR

Q Bio is transforming the annual physical into a fully automated, data-driven assessment that combines whole-body MRI, labs, genetics, and wearables into a Digital Twin of the patient for early detection and continuous health monitoring.
By integrating longitudinal data, Q Bio targets prevention and precise treatment, potentially improving outcomes for heart disease, cancer, diabetes, CKD, and Alzheimer’s, which affect tens of millions of Americans and carry staggering human and economic costs.
Positioned at the intersection of precision medicine, preventive healthcare, and digital twin technologies, Q Bio operates in a rapidly growing market and its streamlined, high-tech model could reduce inefficiencies, improve access, and generate significant cost savings.

Hi friend,

Welcome back to Future Human! Sorry for being quite late this week with our deep dive. Isabelle and Nicholas had their research in order, but I was behind on my end. I didn’t want to fail my first neuro exam, but frankly that’s a poor excuse–newsletter over all!

Here on campus things are settling after the summer. Like I mentioned, we are through one exam for neuro (of seven…). With that behind me, I am feeling better about the future prospects of seeing the sun and friends for the next two months (exam wasn’t so hard). Things are looking up for the fall of 2025.

On the newsletter front, we have a very exciting announcement coming soon. Details are still being finalized with our partner, but I am itching to spread the word ASAP. I started this project a little over 6 months ago (199 days to be precise) and we still remain SUPER small:

221 Future Human readers
366 Future Human LinkedIn followers
4,554 Andrew LinkedIn followers (odd flex, I’m aware)

With that said, healthtech is a tight knit community and seems we are making valuable connections to open impressive doors already. More details to come soon, but let’s just say the Future Human team (currently working from New York, Texas, and North Carolina) may meet in person this fall for a big event.

Okay, before I spoil too much, let’s return to science and technology.

If you follow consumer health, you’ve probably noticed bougie clinics popping up, promising to test everything—blood, genetics, even your gut—only to struggle, fade, or disappear as quickly as they arrived, like Forward Health. There is no doubt your body is full of secrets. Every change, every signal, every tiny shift is silently happening beneath the surface, while the standard physical exam barely scratches it and is rarely updated. Eventually, advanced body scans and data-driven insights will reveal it all, giving a real-time view of your health. The real question is which technologies—and which clinic models—will actually endure long enough to transform the way we care for ourselves.

So with that, let me ask you:

Can technology transform the annual checkup into a lifelong health dashboard, integrating years of data to guide smarter lifestyle choices and medical care?

The Story

Most people think of the annual physical as a stethoscope, a blood draw, and maybe some small talk about diet and exercise. Q Bio thinks of it more like an engineering problem—and wants to rebuild it from the ground up. The company’s mission is to automate every step of the checkup, from data collection to triage and routing, making preventive, personalized healthcare widely accessible. Its flagship vision, the Gemini Exam, brings together advanced MRI imaging, genetic sequencing, lab work, and vital signs into a streamlined, repeatable assessment that could one day be scaled to tens of thousands of patients per clinic each year.¹

The origins of Q Bio trace back to a deeply personal crisis for co-founder Jeff Kaditz, a serial entrepreneur and former co-founder of Affirm. In the wake of a near-fatal accident, Kaditz faced both the failures of the U.S. healthcare system and the fragility of personal health. His insurance company initially refused coverage, forcing him to sell nearly everything he owned to pay his hospital bills. While immobilized in recovery, Kaditz reflected on the experience: not only had the financial system left him stranded, but his physicians struggled to explain what had changed in his body or provide a clear plan for recovery.²^,³

That gap—our inability to continuously and comprehensively monitor health—sparked the idea that became Q Bio. Kaditz envisioned a tool that could capture the state of the human body regularly, non-invasively, and with enough precision to identify changes before they escalated into disease.

“This isn’t screening..This is preparing for something inevitable. We call it health monitoring”

Jeff Kaditz, Co-founder of Q Bio

To bring the idea to life, Kaditz teamed up with Stanford genetics professor Mike Snyder, a pioneer in genomics and early disease detection, and Dr. Garry Choy, a radiologist with experience at the intersection of medicine and technology. Together, they built a platform capable of measuring thousands of biochemical, genetic, and anatomical biomarkers in under an hour—less time than a typical dental appointment. Crucially, the system doesn’t just take snapshots; it continuously aggregates and analyzes a patient’s medical history, making it possible to detect subtle but important shifts over time.⁵

This approach—longitudinal, data-driven, and powered by computation—reflects Q Bio’s ambition to transform medicine from what Kaditz calls “art to science.” While traditional medicine often reacts to disease only after symptoms surface, Q Bio seeks to empower physicians with a dynamic, personalized map of each patient’s biology, enabling earlier interventions and more precise care,

The vision has attracted backing from top investors including Andreessen Horowitz, Khosla Ventures, Founders Fund, and most recently, TELUS Ventures, bringing total funding to $27 million as of June 2024. Today, under the leadership of former Bigfoot Biomedical CEO Jeffrey Brewer, Q Bio continues its push to make what it calls “the Star Trek medbay” a reality.⁴

The Tech

Q Bio is turning blood, MRI scans, and wearable data into what might be the world’s most high-tech health selfie. At the center of this vision is the Gemini Exam, a 75-minute, in-person assessment that layers together imaging, lab testing, genetics, and wearable data into physical exam of the future.

The exam starts with the basics—blood, urine, vitals, and an EKG. Then, the protocol moves to a comprehensive metabolic panel, advanced lipid testing, hormone and endocrine evaluation, rheumatological labs, and a hereditary cancer screen covering 48 genes. When relevant, genetic counseling and sequencing of family members are offered as well. Taken together, these panels aim to create a multidimensional snapshot of each patient’s biology.¹

The most distinctive feature, however, is Q Bio’s proprietary whole-body MRI platform. Just last year, Q Bio introduced Tensor Field Mapping (TFM), a wild MRI technology that delivers detailed, harmonized, and quantifiable imaging data, moving beyond the qualitative limitations of traditional MRIs. Unlike conventional MRIs, which often produce data susceptible to clinical variations, TFM offers reproducible multi-parametric tissue quantification across different machines and clinical settings. This advancement enables consistent and reliable imaging data that can be shared, pooled, and compared, facilitating accurate disease diagnosis and treatment. TFM's capabilities include a 100-fold reduction in computational power. All of this tech confused me in all honesty, so if you are in the same boat, I hope these bullets help simplify things.

Traditional MRI:

Produces pictures of your body
Mostly qualitative — “looks normal” vs “looks abnormal”
Can vary a lot depending on the machine, settings, or technician
Hard to compare scans over time or across hospitals

Q Bio’s Tensor Field Mapping (TFM):

Turns MRI into quantitative data (measures tissue properties as numbers, not just pictures)
Harmonized across machines (same body part will give the same measurements anywhere)
Uses math (Maxwell regularization, field calibration) to reduce errors and artifacts
Very fast computationally
Enables tracking subtle changes over time, supports AI analysis, and helps build “digital twins” of your body

Okay, got it?! It’s okay if not, just know it's a solid leap in MRI.

Data doesn’t stop at the scanner. Wearable integration allows activity, sleep, and heart rate trends to be folded into the same platform, contextualizing the “inside view” with a continuous record of everyday physiology. All of this information is then synthesized into what Q Bio calls a Digital Twin—a living model of the patient’s biology that can be updated with each exam and used to simulate risk, guide interventions, and inform clinical decisions.

On the software side, Gemini’s dashboard reflects Q Bio’s ambition to make this massive dataset not just available, but usable. Features include secure link-based data sharing, search functionality to navigate biomarkers, and downloads of MRI images and lab reports. A 3D anatomical reconstruction powered by the company’s Anatomical Foundation Model (AFM) allows patients and clinicians to visualize organs and tissues interactively. The AFM can now parse more than 300 anatomical structures and generate metrics such as liver iron concentration and muscle-fat fractions—values that can be monitored longitudinally.⁶

Now we get to the caveat—one which has held many clinics back in the past. At $3,495 per exam, Q Bio’s MRI offering is far from cheap. Patients can pay with an HSA or FSA, but without insurance coverage, this remains out of reach for most households. Q Bio frames the price not as a luxury scan, but as part of a new paradigm in proactive medicine: high-resolution, data-rich monitoring designed to detect disease before symptoms appear, shifting care from episodic problem-solving to continuous risk assessment and prevention. If validated and eventually reimbursed, the model could cut downstream costs by catching disease early, potentially reshaping preventive care. But until then, access will remain limited to the wealthiest patients.

The access challenge echoes why Forward Health, despite raising more than $650 million and reaching a $1 billion valuation, ultimately went out of business in 2024. Forward offered a $149/month subscription for tech-heavy primary care through its “CarePods,” but low utilization, technical failures, and a lack of perceived value meant patients weren’t willing to pay out-of-pocket for something insurance didn’t cover. Q Bio risks a similar fate if it stays positioned as a boutique service, but it has one advantage Forward lacked: its technology supplements rather than replaces physicians, with clear potential to generate clinically actionable insights. If insurers embrace its preventive value and prices fall through scale, Q Bio could avoid the “premium club” trap and open access to proactive imaging at population scale.

The Market

Q Bio operates at the intersection of precision medicine, preventive healthcare, and emerging digital twin technologies—a rapidly expanding market with significant growth potential. The global precision medicine market alone was estimated at $87.5 billion in 2023 and is projected to reach $249.2 billion by 2030, growing at a CAGR of 16.3%. Advancements in genomics, rising demand for personalized treatments, and innovations in diagnostics are driving this expansion, particularly in areas like next-generation sequencing (NGS) combined with companion diagnostics, which oncologists expect will play a major role in precision diagnostics and therapeutics.⁸

Parallel to this, the preventive healthcare technologies and services market was valued at $243 billion in 2022 and is expected to reach $585.6 billion by 2030, growing at a CAGR of 11.8%. This growth is fueled by the increasing prevalence of lifestyle-associated and chronic diseases, as well as rising patient demand for proactive health monitoring. Q Bio’s approach—integrating MRI, lab panels, genetics, and wearables into a single exam—positions it squarely within both precision and preventive healthcare segments, offering a unique value proposition compared with traditional diagnostics.¹⁰

In the competitive landscape, Q Bio faces both established players and emerging startups. Large companies such as Siemens, Janssen, Illumina, Quest Diagnostics, Abbott, and QIAGEN dominate genomics, diagnostics, and imaging. In the preventive health space, companies like Myriad Genetics, Merck, GSK, Omnicell, and McKesson are key players. While these incumbents offer strong individual services, few integrate longitudinal imaging, genetic data, and wearables into a comprehensive “health monitoring” platform as Q Bio does.⁸

Emerging digital twin startups also signal the market’s next frontier. ImmuNovus (U.S.) uses digital twins to model immune system trajectories, DeepCARES (Saudi Arabia) leverages multi-omics biosensors for real-time patient monitoring, Twinical (France) builds AI-driven 3D replicas for surgical planning, and CERTAINTY (Germany) simulates cancer progression and treatment response. Q Bio’s Gemini Digital Twin platform follows a parallel path, but in the proactive health management arena.⁶^,¹¹

With these combined market dynamics, Q Bio is positioned to capture a segment of the growing precision and preventive health markets by offering a differentiated product: a high-resolution, data-rich, longitudinal health monitoring system that blends cutting-edge imaging, computational analysis, and real-time data integration. The company’s challenge will be scaling access while demonstrating measurable clinical value in a landscape crowded with specialized diagnostics and emerging AI-driven platforms.

The Sick

Even the world’s best scientists and doctors don’t fully understand why people develop disease differently or respond inconsistently to treatments. Traditional medicine often relies on broad population averages, resulting in a “one-size-fits-all” approach that works for some patients but misses many others. In fact, on average, any given prescription drug only works for about half of those who take it. Personalized and precision medicine aim to change this paradigm, shifting the focus from reaction to prevention, improving disease detection, preempting progression, tailoring prevention strategies, prescribing more effective drugs, avoiding predictable side effects, and reducing the time, cost, and failure rates of clinical trials.¹²^,¹³

Chronic diseases—heart disease, cancer, diabetes, and chronic kidney disease—are the leading causes of illness, disability, and death in the U.S., with six in ten Americans having at least one chronic condition and four in ten having two or more. Lifestyle behaviors such as poor nutrition, physical inactivity, smoking, and excessive alcohol use drive many of these conditions, while social determinants of health, like access to safe spaces, healthy food, and medical care, can further exacerbate risk. We have pitched the value of preventative care before, but in case you forgot, early and proactive intervention is critical because as chronic diseases progress, reversal becomes increasingly difficult and costly.¹⁴^,¹⁵

Q Bio’s technology is designed to intervene at this early stage. By integrating longitudinal data, the platform creates a comprehensive, individualized model of a patient’s biology that allows clinicians to identify emerging risks before they manifest as disease. This approach aligns with the natural progression of disease, which results from a combination of inherited susceptibility and environmental exposures. By tracking multiple risk factors over time, Q Bio can help guide lifestyle adjustments, preventive interventions, or specialist consultations tailored to the individual,

The potential impact spans multiple high-burden conditions. Heart disease and stroke claim more than 944,800 lives annually in the U.S., while cancer affects 1.7 million Americans each year and kills over 600,000. Diabetes impacts more than 38 million Americans, with an additional 98 million at risk due to prediabetes. Chronic kidney disease affects over 35.5 million adults, yet awareness remains extremely low, and Alzheimer’s disease now affects nearly 7 million Americans, with mortality rising 141% since 2000. In each case, earlier, more personalized insights could dramatically improve outcomes.¹⁵

The Economy

Chronic disease doesn’t just take a human toll; it also costs the U.S. economy hundreds of billions every year. Cardiovascular diseases, heart disease and stroke, account for $254 billion in healthcare spending annually, with an additional $168 billion in lost productivity, and costs are projected to reach roughly $2 trillion by 2050 (outrageous). Cancer care is expected to surpass $240 billion by 2030, while diabetes already costs $413 billion each year in medical expenditures and lost productivity. Chronic kidney disease consumes nearly one-quarter of Medicare dollars, totaling $95.7 billion, and Alzheimer’s care is projected to rise from $360 billion in 2024 to nearly $1 trillion by 2050.¹⁶

These staggering numbers are compounded by systemic barriers to access. Over 100 million Americans face challenges in obtaining primary care, a number that has nearly doubled since 2014. Shortages of primary care providers leave almost one-third of the population vulnerable to preventable chronic conditions, as well as emerging public health threats like influenza or COVID-19. Those most affected often earn below 200% of the Federal Poverty Level, creating additional barriers due to travel and out-of-pocket costs. Even among insured adults, many households experience financial strain from medical bills when family members are sick, uninsured, or underinsured, with a large portion of the population delaying or going without necessary care due to cost concerns.¹⁷

To be clear, Q Bio isn’t a silver bullet—at least not yet. Right now, it’s still a VERY premium service, aiming to build enough scale to achieve positive cash flow and eventually bring prices down to a more sustainable level. That said, it has the potential to mitigate both the human and financial costs of disease once it scales. The Gemini Exam is designed to be a fast, reliable, and comprehensive workup that can identify risks and disease earlier than conventional approaches. Early diagnosis and intervention can reduce hospitalizations, avoid ineffective treatments, and improve patient outcomes—all of which translate into meaningful economic savings for both individuals and the broader healthcare system.

Moreover, the convenience of the Gemini Exam—completed in roughly 75 minutes at a single center—helps address access gaps by consolidating diagnostics that might otherwise require multiple appointments across different facilities. It’s an underappreciated feature because it doesn’t sound flashy or “techified,” but if you’ve ever tried to schedule each of these tests separately, you know how transformative that time reduction really is. This streamlined approach not only reduces the time burden on patients but also decreases inefficiencies in the healthcare system, lowering overall costs and improving resource utilization.

Right now, access to comprehensive diagnostics is fragmented, expensive, and often reserved for those with time, money, and connections. But technology has a way of bending that curve—what starts as premium often scales, driving down costs and expanding access to more people. That’s the real promise here: Q Bio isn’t just about detecting disease earlier, it’s about packaging precision diagnostics into a model that could eventually make proactive, personalized care practical and affordable for far more than today’s narrow slice of patients. It is not there yet, but I am hopreful.

My Thoughts

Q Bio isn’t just another boutique health clinic chasing the next wellness trend—it’s attempting to redefine what it means to know your own body. By merging MRI, labs, genetics, and wearables into a continuous, longitudinal model, it tackles a problem most of us don’t even realize exists: that traditional exams are snapshots, blind to the subtle shifts that shape long-term health. The question isn’t whether this technology is impressive—it clearly is—but whether it can scale, prove clinical value, and survive the market realities that have claimed so many luxury health experiments before it. I think it has a shot, but only time will tell if this is the clinic that actually lasts.

To more lives saved,

Andrew

I always appreciate feedback, questions, and conversation. Feel free to reach out on LinkedIn @andrewkuzemczak.